

CURRICULUM VITAE



PERSONAL INFORMATION

Name ANNA TERESA BAGNATO, PHD
 Phone (+39) 06 5266 5618
 Fax (+39) 06 5266 2600
 E-mail annateresa.bagnato@ifo.gov.it
 Date of birth [REDACTED]
 Sex [REDACTED]
 Nationally [REDACTED]

EDUCATION AND TRAINING

July 1984	Degree in Biology at the University of Rome "La Sapienza"
July 1989	Specialization in General Pathology at the University of Rome "La Sapienza"

POSITION HELD

Jan. 1981 – Jul. 1984	Resident student at the University Sapienza of Rome for the Graduation thesis.
Sept. 1984 – Oct. 1985	Enrolled as research fellow in the Regina Elena National Cancer Institute for Cancer Research post- graduation training.
Oct. 1985 – Dec. 1987	Research fellow Italian Association for Cancer Research (AIRC) at the Regina Elena National Cancer Institute
Jan. 1988 – Sept. 1989	Collaboration research at the University of Rome "La Sapienza" in the Institute V Clinica Medica concerning the identifications of receptors for several intragonadal peptides.
Sept. 1989 – July 1991	Guest researcher in the Endocrinology and Reproductive Research Branch, NICH, NIH, Bethesda, MD, USA on project supervised by M.D. Kevin J. Catt concerning the autocrine/paracrine action of ovarian peptides acting on G-protein completed receptors.
Dec. 1991 – pres.	Group Leader in Staff the Laboratory of Molecular Pathology (at the Regina Elena National Cancer Institute (IRE) of Rome, Italy
Jan. 2009-Feb.2016	Responsible Lab. "A" Development Therapeutic Programme Department (IRE) Rome
Feb.2016-pres.	Head of Preclinical Models and New Therapeutic Agents Unit (IRE)

PERSONAL STATEMENT

	Dr.Bagnato's research has identified the key role of the endothelin axis in the development and the progression of cancer and in the acquisition of chemoresistance, in particular in ovarian and colon carcinoma and cutaneous melanoma model. The participation to an international network produced important preclinical contributions defining the role of endothelin axis in human tumors which represent the translational basis that will lead to the introduction of novel targeted therapies in the ovarian cancer management. She is author of 110 scientific publications on peer reviewed journals (PNAS, Nature Rev. Cancer, Cancer Research, Nat. Commun.) with a H-index of 41 (Scopus) and a total of 5437 citations.
--	--

CLINICAL STUDIES

	"A phase II, Double-blind, Placebo-controlled, Multi-centre, Randomised Study of ZD4054 plus Carboplatin and Paclitaxel or Placebo plus Carboplatin and Paclitaxel in Patients with Advanced Ovarian Cancer Sensitive to Platinum-based Chemotherapy" Principal Translational Scientist: Dr.ssa Anna Bagnato
--	--

PROFESSIONAL ACTIVITIES

2019-pres.	Member of Institutional Committee of Patient Centrality
2017-pres.	Member of Institutional Committee of Gender Medicine
2015-pres.	Member of AIRC Technical Scientific Committee
1992-pres.	Principal Investigator of differents grants by public and private agencies and by the industry
2000-pres.	Reviewing in indexed International journals and in Grant cancer research agencies
2016-pres.	Member of Editorial Board J. Exp. Clin. Cancer Res.
2007-2019	Organizing Committee 10-16 Int. Conference on Endothelin
2010	Organizing Committee 52 Annual Meeting of the Italian Cancer Society (SIC), Rome, Italy 2010
2010-2013	Member of SIC Board
2011-pres.	Member of different national and international Award for Cancer Research Selection Committee
2011-pres.	Supervisor for undergraduated and PhD students of Universities of Rome, and for fellows granted by public and private agency
2001-pres.	Lecturer, Chairman or Invited Speaker at numerous international and national meetings
2003-pres.	Media interviews/Articles

PROFESSIONAL SOCIETIES

<ul style="list-style-type: none">- Member Italian Society of Cancerology- Member European Association for Cancer Research- Member American Association for Cancer Research

AWARDS AND HONORS

<ul style="list-style-type: none">- Nature Review Cancer Prize CNIO Cancer conference, Cadherins, Catenins and Cancer, Madrid, November 19 December 1, 2004- National Award "Virginia Centurione Bracelli", April, 15, 2012- National Award "Roche per la Ricerca" 2016

Publications (last 5 years)

90. Rosanò L. and Bagnato A. Disrupting endothelin and Wnt relationship to overcome chemoresistance. Mol. Cell. Oncology 2:3, e995025; 2015
91. Semprucci E, Tocci P, Cianfrocca R, Sestito R, Caprara V, Vegliione M, Castro VD, Spadaro F, Ferrandina G, Bagnato A*, Rosanò L. Endothelin A receptor drives invadopodia function and cell motility through the β -arrestin/PDZ-RhoGEF pathway in ovarian carcinoma. Oncogene. 2015 doi: 10.1038/onc.2015.403 (*co-corr. author)
92. Sestito R., Cianfrocca R., Rosanò L., Tocci P., Semprucci E., Di Castro V., Caprara V., Ferrandina G., Sacconi A., Blandino G., Bagnato A. miR-30a inhibits endothelin A receptor and chemoresistance in ovarian carcinoma. Oncotarget 7:4009-23, 2016
93. Tocci P, Cianfrocca R, Sestito R, Caprara V, Di Castro V, Bagnato A, Rosanò L. Endothelin-1/endothelinA receptor axis activates RhoAGTPase in epithelial ovarian cancer. Life Sci. 159, 49-54, 2016
94. Sestito R., Cianfrocca R. Rosanò L., Tocci P., Di Castro V., Caprara V., Bagnato A. Macitentan blocks endothelin-1 receptor activation required for chemoresistant ovarian cancer cell plasticity and metastasis. Life Sci. 159, 43-48, 2016
95. Rosanò L and Bagnato A. Endothelin therapeutics in cancer: where are we? Am J PhysiolRegullIntegr Comp Physiol.310, 469-75, 2016
96. Cianfrocca R., Tocci P., Rosanò L., Caprara V., Sestito R., Di Castro V., Bagnato A. Nuclear β -arrestin-1 is a critical cofactor of hypoxia-inducible factor-1 α signaling in endothelin-1-induced ovarian tumor progression. Oncotarget 7:17790-804, 2016
97. Rosanò L and Bagnato A. β -arrestin1 at the cross-road of endothelin-1 signaling in cancer. J. Exp. Clin. Cancer Res. 35 (1) 121, 2016

98. Bagnato A and Rosanò L Endothelin-1 receptor drives invadopodia: Exploiting how β -arrestin-1 guides the way. *Small GTPase* 2016:1-5.

99. Russignan A, Spina C, Tamassia N, Cassaro A, Rigo A, Bagnato A, Rosanò L, Bonalumi A, Gottardi M, Zanatta L, Giacomazzi A, Scupoli MT, Tinelli M, Salvadori U, Mosna F, Zamò A, Cassatella MA, Vinante F, Tecchio C. Endothelin-1 receptor blockade as new possible therapeutic approach in multiple myeloma. *Br. J. Haematology*.178:781-793, 2017

100. Rosanò L and Bagnato A. Targeting endothelin-1 receptor/ β -arrestin network for the treatment of ovarian cancer. *Exp. Op. Therap. Target*. 21:925-932,2017

101. Cianfrocca R, Rosanò L, Tocci P, Sestito R, Caprara V, Di Castro V, De Maria R, Bagnato A. Blocking endothelin-1-receptor/ β -catenin circuit sensitizes to chemotherapy in colorectal cancer. *Cell Death Differ*.24:1811-1820,2017

102. Di Modugno F, Caprara V, Chellini L, Tocci P, Spadaro F, Ferrandina G, Sacconi A, Blandino G, Nisticò P, Bagnato A*, Rosanò L. hMENA is a key regulator in endothelin-1/ β -arrestin1-induced invadopodial function and metastatic process. *Proc Natl Acad Sci USA*.115:3132-3137, 2018. (*co-corr. author)

103. Russignan A, Spina C, Tamassia N, Cassaro A, Rigo A, Bagnato A, Rosanò L, Bonalumi A, Gottardi M, Zanatta L, Giacomazzi A, Scupoli MT, Tinelli M, Salvadori U, Mosna F, Zamò A, Cassatella MA, Vinante F, Tecchio C. In reply to Schäfer et al: New evidence on the role of Endothelin-1 axis as a potential therapeutic target in Multiple Myeloma. *Br. J. Haematology*. 2018 May 4. doi: 10.1111/bjh.15240

104. Chellini L, Caprara V, Spadaro F, Sestito R, Bagnato A, Rosanò L. Regulation of extracellular matrix degradation and metastatic spread by IQGAP1 through endothelin-1 receptor signalling in ovarian cancer. *Matrix Biol*. 2018 Oct 25. pii: S0945-053X(18)30303-2.

105. Bagnato A, Rosanò L. New routes in GPCR/ β -arrestin-driven signalling in cancer progression and metastasis. *Front. Pharmacol*. Feb. 2019. doi: 10.3389/fphar.2019.00114

106. Rosanò L, Cianfrocca R, Bagnato A. Methods to Investigate β -Arrestin-1/ β -Catenin Signaling in Ovarian Cancer Cells. *Methods Mol Biol*.2019;1957:393-406. doi: 10.1007/978-1-4939-9158-7_25

107. Rosanò L, Bagnato A. New insights into the regulation of the actin cytoskeleton dynamics by GPCR/ β -arrestin in cancer invasion and metastasis. *Int Rev Cell Mol Biol*. 2019;346:129-155. doi: 10.1016/bs.ircmb.2019.03.002.

108. Tocci P, Cianfrocca R, Di Castro V, Rosanò L, Sacconi A, Donzelli S, Bonfiglio S, Bucci G, Vizza E, Ferrandina G, Scambia G, Tonon G, Blandino G, Bagnato A. β -arrestin1/YAP/mutant p53 complexes orchestrate the endothelin A receptorsignaling in high-grade serous ovarian cancer. *Nat Commun*. 2019 Jul19;10(1):3196. doi: 10.1038/s41467-019-11045-8

109. Tocci P, Rosanò L, Bagnato A. Targeting Endothelin-1 Receptor/ β -Arrestin-1 Axis in Ovarian Cancer: From Basic Research to a Therapeutic Approach. *Front Endocrinol (Lausanne)*. 2019 Sep 4;10:609. doi: 10.3389/fendo.2019.00609.

Book Chapters

1. Bagnato A, Natali P.G.: Targeting endothelin axis in cancer. In *Molecular targeting and signal transduction*. Edited by Kumar R: Kluwer Academic Publishers; 293-314, 2004.

2. Bagnato A. Therapeutic targeting of the endothelin receptor in cancer. In: *Cancer Therapy: Molecular targets in tumor-host Interactions*. ed: G.F. Weber 169-186. Horizon Bioscience 2005.

3. Bagnato A. Tumori In "Antagonisti recettoriali dell'endotelina quali composti e quali patologie" Eds A. Benigni, G. Remuzzi. Il pensiero Scientifico Editore pp. 77-86, 2008.